<p>Circular RNA MYLK Promotes Hepatocellular Carcinoma Progression Through the miR29a/KMT5C Signaling Pathway</p>

Circular RNA MYLK as a prognostic biomarker in patients with cancers: A systematic review and meta‐analysis

“…Moreover, one review article and one investigation with only bioinformatic analysis were excluded after full‐text reviews (Figure 1 ). Ultimately, 12 studies were included in the qualitative synthesis of this review 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 21 , 22 (Table 1 ); however, three studies did not provide data regarding prognostic or clinicopathological features 12 , 21 , 22 ; therefore, nine articles were included in the meta‐analysis. Seven of these studies investigated the prognostic significance of circMYLK, and nine studies ascertained the clinicopathological importance of circMYLK in patients with malignancies.…”

“…All studies were from China and published between 2017 and 2021. Using the quantitative real‐time polymerase chain reaction (qRT‐PCR), the studies revealed upregulation of circMYLK in different malignant tissue samples, including bladder cancer, 7 , 8 HCC, 10 , 11 laryngeal cancer, 12 , 13 NSCLC, 9 renal cancer, 14 ovarian cancer, 15 prostate cancer, 22 cervical cancer, 21 and colorectal cancer. 16 According to these studies, circMYLK acts as a tumor promoter circRNA leading to migration, invasion, proliferation, and metastasis of neoplastic cells and inhibiting their apoptosis through interaction with several miRNAs and corresponding downstream signaling pathways.…”

“…Concerning the prognostic endpoint, seven studies consisting of 464 patients addressed the OS of patients with six distinct malignancies (two studies for HCC and one study for renal cancer, bladder cancer, NSCLC, ovarian cancer, and colorectal cancer) with the maximum follow‐up duration ranging from 30 to 100 months (Table 2 ). 7 , 9 , 10 , 11 , 14 , 15 , 16 Based on NOS, the methodological quality of included studies was six to seven out of nine scores, mainly lacking the scores for adjustment factors (Figure S1 ). All studies determined upregulation of circMYLK to be associated with poor OS of patients with the mentioned cancers, with the pooled HR = 1.75 [(95% CI 1.52–2.02); P < 0.01] (Figure 2 ).…”

“… 7 Current investigations have found the oncogenic role of circMYLK, which is overexpressed in several cancer types, including bladder cancer, 7 , 8 non‐small‐cell lung cancer (NSCLC), 9 and hepatocellular carcinoma (HCC). 10 , 11 This circular transcript participates in cancer‐related critical pathways, such as VEGFA/VEGFR2, MEK/ERK, and NF‐κB pathways. 7 , 12 Furthermore, several studies have suggested that circMYLK expression is associated with the various malignancies' prognosis and clinicopathological characteristics.…”

“… 7 , 12 Furthermore, several studies have suggested that circMYLK expression is associated with the various malignancies' prognosis and clinicopathological characteristics. 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 Despite these promising results, no prior studies have comprehensively reviewed the relationship between circMYLK expression and clinical outcomes of cancer patients. Herein, we carried out a systematic review and meta‐analysis to determine the role of circMYLK in cancer progression and provide a precise predictive value of circMYLK in the prognosis and clinicopathological features of patients with various cancers.…”